Skip to main content
PTCT
NASDAQ Life Sciences

PTC Therapeutics Swings to Profit in Q2, Raises Guidance on Sephience Launch and Novartis Milestone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$75.49
Mkt Cap
$6.264B
52W Low
$43.175
52W High
$90.87
52W Position info
75% above low
Off High info
17% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PTCT sits 75% above its 52-week low of $43.175.

Summary

PTC Therapeutics reported Q2 2026 revenue of $361 million, net income of $83.5 million, and raised full-year guidance. The quarter was driven by the Sephience launch and a $50 million milestone from Novartis. The company completed a $550 million convertible note offering, strengthening its balance sheet.


Key Events · Earnings and Guidance · PTCT

  • Q2 Revenue Surges to $361M

    Total revenue reached $361 million, up 102% year-over-year, driven by $151 million in Sephience sales and a $50 million milestone from Novartis for initiating the Phase 3 votoplam trial.

  • Swings to Profitability

    Net income came in at $83.5 million ($0.92 diluted EPS), compared to a net loss of $64.8 million in Q2 2025, reflecting operating leverage from product launches.

  • Full-Year Guidance Raised

    Management raised full-year 2026 guidance, citing strong Sephience uptake and milestone revenue, signaling confidence in sustained growth.

  • Balance Sheet Strengthened

    The company completed a $550 million 0% convertible notes offering due 2031; proceeds were used to repurchase $222 million of 2026 notes, extending maturity and reducing near-term debt. Cash and marketable securities totaled $2.23 billion at quarter-end.


Analysis · PTCT · Life Sciences

A strong second quarter saw PTC Therapeutics deliver total revenue of $361 million, fueled by the Sephience launch and a $50 million milestone from Novartis. The company swung to a net profit of $83.5 million and raised its full-year guidance. A $550 million convertible note offering further strengthened the balance sheet, extending the cash runway. Reflecting the product's commercial success, Sephience sales triggered a $30 million milestone payment to former Censa securityholders. These results mark a significant financial turnaround and validate the company's pipeline strategy.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTCT was trading at $75.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $43.18 to $90.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTCT - Latest Insights

PTCT
Nov 03, 2026, 7:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $61.39
Real-time Price: $63.50 info
Change: +$2.11 (+3%) info
Market Cap: $5.359B info
PTCT
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $62.00
Real-time Price: $63.50 info
Change: +$1.50 (+2%) info
Market Cap: $5.359B info
PTCT
Oct 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $60.00
Real-time Price: $63.50 info
Change: +$3.50 (+6%) info
Market Cap: $5.359B info
PTCT
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $64.57
Real-time Price: $63.50 info
Change: -$1.06 (-2%) info
Market Cap: $5.359B info
PTCT
Aug 28, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $70.09
Real-time Price: $63.50 info
Change: -$6.59 (-9%) info
Market Cap: $5.359B info